EP3744333A4 - Medicinal composition for treating diseases associated with increase in expression level of periostin or change in splicing variant thereof - Google Patents

Medicinal composition for treating diseases associated with increase in expression level of periostin or change in splicing variant thereof Download PDF

Info

Publication number
EP3744333A4
EP3744333A4 EP19743472.3A EP19743472A EP3744333A4 EP 3744333 A4 EP3744333 A4 EP 3744333A4 EP 19743472 A EP19743472 A EP 19743472A EP 3744333 A4 EP3744333 A4 EP 3744333A4
Authority
EP
European Patent Office
Prior art keywords
periostin
increase
change
expression level
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19743472.3A
Other languages
German (de)
French (fr)
Other versions
EP3744333A1 (en
Inventor
Fumihiro SANADA
Yoshiaki Taniyama
Ryuichi Morishita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of EP3744333A1 publication Critical patent/EP3744333A1/en
Publication of EP3744333A4 publication Critical patent/EP3744333A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EP19743472.3A 2018-01-25 2019-01-23 Medicinal composition for treating diseases associated with increase in expression level of periostin or change in splicing variant thereof Pending EP3744333A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018010354 2018-01-25
PCT/JP2019/002015 WO2019146621A1 (en) 2018-01-25 2019-01-23 Medicinal composition for treating diseases associated with increase in expression level of periostin or change in splicing variant thereof

Publications (2)

Publication Number Publication Date
EP3744333A1 EP3744333A1 (en) 2020-12-02
EP3744333A4 true EP3744333A4 (en) 2021-11-03

Family

ID=67395945

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19743472.3A Pending EP3744333A4 (en) 2018-01-25 2019-01-23 Medicinal composition for treating diseases associated with increase in expression level of periostin or change in splicing variant thereof

Country Status (4)

Country Link
US (1) US20210047642A1 (en)
EP (1) EP3744333A4 (en)
JP (1) JP7261482B2 (en)
WO (1) WO2019146621A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4534092B2 (en) * 2000-09-08 2010-09-01 第一三共株式会社 Heart failure treatment
CN101888855A (en) 2007-06-27 2010-11-17 阿斯比奥制药株式会社 Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
US9012425B2 (en) 2011-06-10 2015-04-21 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for the treatment of Leber congenital amaurosis
US9340783B2 (en) 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
WO2014136910A1 (en) 2013-03-08 2014-09-12 国立大学法人大阪大学 ANTIBODY TO PEPTIDE ENCODED BY Exon-21 OF PERIOSTIN, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE CONTAINING SAID ANTIBODY
GB201504124D0 (en) 2015-03-11 2015-04-22 Proqr Therapeutics B V Oligonucleotides
FR3044926B1 (en) 2015-12-09 2020-01-31 Genethon EFFICIENT GENE THERAPY TOOLS FOR JUMPING DYSTROPHIN EXON 53
WO2018030451A1 (en) * 2016-08-09 2018-02-15 学校法人大阪医科薬科大学 Therapeutic agent for adhesion, method for treating adhesion, postoperative adhesion marker, and method for examining susceptibility to postoperative adhesion

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MURATSU JUN ET AL: "NDT Abstract Supplement 2018", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 33, no. suppl_1, 1 May 2018 (2018-05-01), GB, pages i1 - i660, XP055835259, ISSN: 0931-0509, Retrieved from the Internet <URL:https://academic.oup.com/ndt/article-pdf/33/suppl_1/i471/24824435/gfy104.sp371.pdf> DOI: 10.1093/ndt/gfy104 *
NAKAMA TAKAHITO ET AL: "Different roles played by periostin splice variants in retinal neovascularization", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 153, 12 October 2016 (2016-10-12), pages 133 - 140, XP029812559, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2016.10.012 *
RYUICHI MORISHITA: "Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 28, 1 January 2011 (2011-01-01), pages 181 - 186, XP055184380, ISSN: 1107-3756, DOI: 10.3892/ijmm.2011.712 *
TOMARU A ET AL: "Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis", GENE THERAPY, vol. 24, no. 11, 1 November 2017 (2017-11-01), GB, pages 706 - 716, XP055836213, ISSN: 0969-7128, Retrieved from the Internet <URL:https://www.nature.com/articles/gt201780.pdf> DOI: 10.1038/gt.2017.80 *

Also Published As

Publication number Publication date
EP3744333A1 (en) 2020-12-02
WO2019146621A1 (en) 2019-08-01
US20210047642A1 (en) 2021-02-18
JPWO2019146621A1 (en) 2021-01-07
JP7261482B2 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
EP3840730A4 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
EP3463315A4 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
EP3515444A4 (en) Composition for treating ocular diseases and methods of usage and making
IL278041A (en) Buffered formulations of bevacizumab for use of treating diseases
EP3351219A4 (en) Material for optical treatment of eye diseases
EP3752215A4 (en) Extracorporeal devices and methods of treating complement factor related diseases
EP3707275A4 (en) Dosage and varietal recommendations for the treatment of medical conditions using cannabis
EP3863630A4 (en) Compositions and methods for the treatment of presbyopia
EP3969597A4 (en) Compositions and methods for the treatment of atpase-mediated diseases
EP3761970A4 (en) Compositions and methods for the treatment of neurological diseases
EP3799570A4 (en) Modulators of apol1 expression
EP3737379A4 (en) Compositions and methods for treating metabolic diseases
EP3902525A4 (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3849591A4 (en) Methods and compositions for treating skin diseases
EP3654964A4 (en) Composition and methods for the treatment of myopia
EP3866786A4 (en) Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof
EP3880690A4 (en) Peptides and pharmaceutical compositions for treating eye diseases
EP3766508A4 (en) Crude drug composition for preventing or treating respiratory diseases
EP3744347A4 (en) Composition for skin diseases treatment use
EP3737370A4 (en) Compositions and methods for treating pain with wogonin
EP3538083A4 (en) Formulations for the treatment of ocular surface diseases and related methods
EP3533451A4 (en) Application of paeoniflorin-6&#39;-o-benzene sulfonate in medicine for treating sjögren&#39;s syndrome
EP3362096A4 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
EP3268020A4 (en) Use of isolated fractions of mastic gum for treating optic neuropathy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200805

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031711000

Ipc: C12N0015113000

A4 Supplementary search report drawn up and despatched

Effective date: 20211001

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20210927BHEP

Ipc: A61P 37/08 20060101ALI20210927BHEP

Ipc: A61P 35/04 20060101ALI20210927BHEP

Ipc: A61P 35/00 20060101ALI20210927BHEP

Ipc: A61P 29/00 20060101ALI20210927BHEP

Ipc: A61P 27/02 20060101ALI20210927BHEP

Ipc: A61P 19/02 20060101ALI20210927BHEP

Ipc: A61P 17/00 20060101ALI20210927BHEP

Ipc: A61P 13/12 20060101ALI20210927BHEP

Ipc: A61P 11/06 20060101ALI20210927BHEP

Ipc: A61P 11/00 20060101ALI20210927BHEP

Ipc: A61P 9/10 20060101ALI20210927BHEP

Ipc: A61P 9/04 20060101ALI20210927BHEP

Ipc: A61K 48/00 20060101ALI20210927BHEP

Ipc: A61K 35/76 20150101ALI20210927BHEP

Ipc: A61K 31/711 20060101ALI20210927BHEP

Ipc: C12N 15/113 20100101AFI20210927BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526